United Kingdom pharmaceutical market is expected to register robust growth in the forecast period, 2023-2027. Innovations in the fields of oncology, autoimmune, and diabetes treatment will continue to augment the United Kingdom pharmaceutical market. Emerging markets will see a steady rise is people seeking treatment for these diseases owing to the advancements in treatments and prevention will continue to propel the market growth. Growing number of patients who experience chronic ailments or pain which drives the market growth. In addition to this, chronic illness including hypertension and mental health issues are key driver of the growth in pharmaceutical market in United Kingdom. The pharmaceuticals that treat rare diseases as advancements in pharmaceuticals offer numerous solutions and up-gradations in medicine uncover more problems.
The Expanding Geriatric Population is Projected to Fuel the Market Growth
Chronic conditions are on the rise and patients are often suffering from more than just one ailment. This development is intensified owing to the growing middle-class and escalating adoption of sedentary lifestyles in emerging markets, which results into obesity, diabetes, and other costly health conditions. Chronic noncommunicable disease prevalence such as cardiovascular diseases or cancer are accelerating the demand for pharmaceuticals. The increasing elderly population and the high requirement of more medical care especially to older population are driving the growth of the pharmaceutical market. Government health programs including Medicaid and Medicare enable a wider range of seniors to be covered. Additionally, advancements in healthcare that people are living longer and requiring services for a longer period.
Growing Number of Chronic Diseases is Expected to Bolster the Market Growth
The escalating demand for healthcare and innovative solutions is one of the primary factors propelling the market growth. Digitalization, big data and artificial intelligence drives the transformation of the pharmaceutical sector and allow companies to enhance drug development and patient care beyond the treatment of diseases, which provide a new revenue stream. For patient care, digital solutions allow the shift from a disease focus to an integrated approach from prevention, screening, diagnostic, treatment, and aftercare. Continuous technological advancement and novel therapeutic approaches have the potential to not only treat, but also assist in curing diseases – or identifying and eliminating risk factors before a disease develops. Part of this development are personalized therapies, a promising approach tailoring medical treatment to the individual characteristics of each patient. The emerging associations between the human microbiome, health and disease are leading to novel diagnostics and therapeutics thereby improving personalized medicine. All these aforementioned factors are expected to augment the pharmaceutical market across United Kingdom during the forecast years.
DOWNLOAD FREE SAMPLE REPORT
Market Segmentation
The United Kingdom Pharmaceutical market is segmented into drug type, product type, application, distribution channel, regional distribution, and competitive landscape. Based on drug type, the market is bifurcated into generic drugs and branded drugs. Based on product type, the market is divided into prescription drugs and over-the-counter drugs. Based on application, the market is segmented into cardiovascular, musculoskeletal, oncology, anti-infective, metabolic disorder, others. Based on end user, the market is divided into
Market Players
Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc., Vertex Pharmaceuticals (U.K.) Limited, Pfizer Limited, Novartis UK Limited, AstraZeneca UK Limited, Bristol-Myers Squibb Pharmaceuticals Limited, Roche Products Limited, Sanofi UK, Sun Pharmaceuticals UK Limited are the key market players operating in United Kingdom Pharmaceutical market.
Attribute | Details |
Base Year | 2021 |
Historic Data | 2017 – 2020 |
Estimated Year | 2022 |
Forecast Period | 2023 – 2027 |
Quantitative Units | Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027 |
Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments covered | · Drug Type · Product Type · Application · Distribution Channel |
Regional scope | London, Southeast, East Anglia, Scotland, Southwest, East Midlands, Yorkshire & Humberside, Rest of United Kingdom |
Key companies profiled | Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc., Vertex Pharmaceuticals (U.K.) Limited, Pfizer Limited, Novartis UK Limited, AstraZeneca UK Limited, Bristol-Myers Squibb Pharmaceuticals Limited, Roche Products Limited, Sanofi UK, Sun Pharmaceuticals UK Limited |
Customization scope | 10% free report customization with purchase. Addition or alteration to regional & segment scope. |
Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |